Latest long-term debt for ASND: $390M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ASND shows a long-term debt of $390M. That compares with $360M in the prior-year period — up 8.2% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ASND's long-term debt is now $390M (was $360M) — a 8.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ascendis Pharma A/S is outperforming or lagging.
Tracking ASND's long-term debt over time shows whether Ascendis Pharma A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $390M That compares with $360M in the prior-year period — up 8.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Ascendis Pharma A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $390M) with ownership activity and broader fundamentals.
Ascendis Pharma A/S's long-term debt is $390M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.